CAMBRIDGE, MA-Ipsen has announced plans to relocate its US research and development operations from Milford, MA to Cambridge—a hub for biotechnology research. This site will be key for innovation in targeted therapies across Ipsen's specialty areas as well as a center of excellence for peptides (a medicine type), according to the company. The move also brings Ipsen closer to several key partners based in the Cambridge area, including prominent hospitals, medical schools, biotech companies and universities,
The company signed an eleven-year lease on 62,600 rentable square-feet of laboratory and office space within a 282,000 square-foot building, located at 650 E. Kendall Street. The deal was brokered by Cresa Corporate Real Estate's Adam Subber, principal. The property is owned by BioMed Realty Trust Inc.
“Relocation to Cambridge represents a major leap forward for our R&D activities,” says Claude Bertrand, EVP and chief scientific officer. “After the acquisition of Syntaxin, a company at the cutting edge of toxin research, this move is another positive milestone in the consolidation of Ipsen's global leadership in peptides.”
Adds Cynthia Sylvestre, president of biomeasure, and Milford site head, “This move reflects our commitment to remain at the cutting edge of research and development to ultimately provide life-saving therapies to patients in need.”
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.